Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte- macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3264-3270

  Cheung, Nai Kong V ^a   Cheung, Irene Y ^a   Kushner, Brian H ^a   Ostrovnaya, Irina ^a   Chamberlain, Elizabeth ^a   Kramer, Kim ^a   Modak, Shakeel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CHILD; DRUG DOSE INCREASE; ERYTHEMA; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; STEM CELL TRANSPLANTATION; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; INFANT; ISOTRETINOIN; MALE; NEUROBLASTOMA; REMISSION INDUCTION;

EID: 84866623753     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.3807     Document Type: Article

References (52)

1. Maris JM: Recent advances in neuroblastoma. N Engl J Med 362:2202-2211, 2010
2. Matthay KK, Reynolds CP, Seeger RC, et al: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study. J Clin Oncol 27:1007-1013, 2009
3. Yu AL, Gilman AL, Ozkaynak MF, et al: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334, 2010
4. Laverdière C, Liu Q, Yasui Y, et al: Long-term outcomes in survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 101:1131-1140, 2009
5. Hobbie WL, Moshang T, Carlson CA, et al: Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 51:679-683, 2008
6. Cheung NK, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987
7. Dillman RO: Cancer immunotherapy. Cancer Biother Radiopharm 26:1-64, 2011
8. Modak S, Cheung NK: Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 25:67-77, 2007
9. Barker E, Mueller BM, Handgretinger R, et al: Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51:144-149, 1991
10. Metelitsa LS, Gillies SD, Super M, et al: Antidisialoganglioside/ granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 99:4166-4173, 2002
11. Batova A, Kamps A, Gillies SD, et al: The ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res 5:4259-4263, 1999
12. Cheung IY, Hsu K, Cheung NK: Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 30:426-432, 2012
13. Kushner BH, Kramer K, Cheung NK: Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19:4189-4194, 2001
14. Kushner BH, Kramer K, LaQuaglia MP, et al: Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 22:4888-4892, 2004
15. Kushner BH, Kramer K, Modak S, et al: Camptothecin analogs (irinotecan or topotecan) plus highdose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res 10:84-87, 2004
16. Kushner BH, Cheung NK, Kramer K, et al: Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 28:551-556, 2001
17. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
18. Cheung NK, Kushner BH, Cheung IY, et al: Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16:3053-3060, 1998
19. Cheung NK, Cheung IY, Canete A, et al: Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54:2228-2233, 1994
20. Cheung NK, Heller G, Kushner BH, et al: Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive? J Clin Oncol 15:2807-2817, 1997
21. Cheung IY, Lo Piccolo MS, Kushner BH, et al: Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 21:3853-3858, 2003
22. Cheung IY, Feng Y, Gerald W, et al: Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 14:7020-7027, 2008
23. Cheung NK, Sowers R, Vickers AJ, et al: FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 24:2885-2890, 2006
24. Hsu KC, Liu XR, Selvakumar A, et al: Killer Ig-like receptor haplotype analysis by gene content: Evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 169:5118-5129, 2002
25. Venstrom JM, Zheng J, Noor N, et al: KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 15:7330-7334, 2009
26. Kushner BH, Cheung IY, Kramer K, et al: High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: Broad implications for immunotherapy. Pediatr Blood Cancer 48:430-434, 2007
27. Kushner BH, Kramer K, Modak S, et al: Topotecan, thiotepa, and carboplatin for neuroblastoma: Failure to prevent relapse in the central nervous system. Bone Marrow Transplant 37:271-276, 2006
28. Kushner BH, Kramer K, Modak S, et al: Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24:5271-5276, 2006
29. Kramer K, Kushner BH, Modak S, et al: Compartmental intrathecal radioimmunotherapy: Results for treatment for metastatic CNS neuroblastoma. J Neurooncol 97:409-418, 2010
30. London WB, Castel V, Monclair T, et al: Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group project. J Clin Oncol 29:3286-3292, 2011
31. Petrella T, Quirt I, Verma S, et al: Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review. Cancer Treat Rev 33:484-496, 2007
32. George RE, Li S, Medeiros-Nancarrow C, et al: High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 24:2891-2896, 2006
33. Matthay KK, Atkinson JB, Stram DO, et al: Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Children's Cancer Group pilot study. J Clin Oncol 11:2226-2233, 1993
34. Matthay KK, Brisse H, Couanet D, et al: Central nervous system metastases in neuroblastoma: Radiologic, clinical, and biologic features in 23 patients. Cancer 98:155-165, 2003
35. Kramer K, Kushner B, Heller G, et al: Neuroblastoma metastatic to the central nervous system: The Memorial Sloan-Kettering Cancer Center experience and a literature review. Cancer 91:1510-1519, 2001
36. Musolino A, Ciccolallo L, Panebianco M, et al: Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: Epidemiological and clinical data from a population-based cancer registry study. Cancer 117:1837-1846, 2011
37. Matthay KK, Edeline V, Lumbroso J, et al: Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486-2491, 2003
38. Schmidt M, Simon T, Hero B, et al: The prognostic impact of functional imaging with (123)Im-IBG in patients with stage 4 neuroblastoma > 1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97. Eur J Cancer 44:1552-1558, 2008
39. Katzenstein HM, Cohn SL, Shore RM, et al: Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 22:3909-3915, 2004
40. Pearson AD, Pinkerton CR, Lewis IJ, et al: High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 9:247-256, 2008
41. Ladenstein R, Pötschger U, Hartman O, et al: 28 years of high-dose therapy and SCT for neuroblastoma in Europe: Lessons from more than 4000 procedures. Bone Marrow Transplant 41:S118-S127, 2008 (suppl 2)
42. Borowitz MJ, Devidas M, Hunger SP, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 111:5477-5485, 2008
43. Marin D, Ibrahim AR, Lucas C, et al: Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232-238, 2012
44. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003
45. Musolino A, Naldi N, Bortesi B, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796, 2008
46. Kushner B, Kramer K, Modak S, et al: Anti-GD2 anitbody 3F8 plus granulocyte-macrophage colony stimulating factor (GM-CSF) for primary refractory neuroblastoma (NB) in the bone marrow (BM). Proc Amer Soc Clin Oncol 25:526s, 2007
47. Venstrom JM, Zheng J, Kushner B, et al: NK cell killer Ig-like receptor (KIR) genotype as a novel biomarker for neuroblastoma patients receiving anti-GD2 monoclonal antibody 3F8. 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010 (abstr 5586)
48. Cho D, Shook DR, Shimasaki N, et al: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16:3901-3909, 2010
49. Tarek N, Gallagher MM, Zheng J, et al: Unlicensed natural killer cells dominate neuroblastoma killing in the presence of anti-GD2 monoclonal antibody. J Clin Invest (in press)
50. Leung W, Handgretinger R, Iyengar R, et al: Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 97:539-542, 2007
51. Delgado DC, Hank JA, Kolesar J, et al: Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70:9554-9561, 2010
52. Cheung NK, Guo HF, Heller G, et al: Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 6:2653-2660, 2000